Genital herpes

CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China

Retrieved on: 
Monday, January 22, 2024
Senior, Lupus, Paresthesia, Heat, Diabetes, Face, FLX, Blister, Growth, CPT, Epilepsy, Bausch Health, Genital herpes, Breastfeeding, Burns, Hypoesthesia, Glycine mollis, Eyelid, National Medical Products Administration, BHC, NMPA, Medical device

[See *Correction above: The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration.]

Key Points: 
  • [See *Correction above: The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration.]
  • "The approval of Thermage FLX, and the TR-4 return pad, marks a significant milestone for Solta Medical," Thomas J. Appio, Bausch Health Chief Executive Officer, said.
  • "The approval from NMPA means we are able to continue the momentum of the growth of Thermage in China," Jiny Kim, Senior Vice President, Solta Medical, said.
  • Ask your doctor for more information about Thermage FLX and see www.thermage.com for additional details.

FDA Approves First Nonprescription Daily Oral Contraceptive

Retrieved on: 
Thursday, July 13, 2023
Vaginal bleeding, Pregnancy, Headache, Syphilis, Laboratoires Pierre Fabre, Bleeding, HIV, Center for Drug Evaluation and Research, Prenatal care, Condom, Cancer, Gonorrhea, Cramp, Hepatitis B, Perrigo, Appetite, Abdominal pain, Dizziness, AIDS, Wart, Risk, Child, Norgestrel, Genital herpes, Vertically transmitted infection, Nausea, Bloating, Chlamydia, Amenorrhea, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Breast cancer, Birth control, Pharmaceutical industry

Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.

Key Points: 
  • Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.
  • "Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, M.D., director of the FDA's Center for Drug Evaluation and Research.
  • "When used as directed, daily oral contraception is safe and is expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy."
  • Opill also should not be used together with another hormonal birth control product such as another oral contraceptive tablet, a vaginal ring, a contraceptive patch, a contraceptive implant, a contraceptive injection or an IUD (intra-uterine device).

NEW SEXUAL TELEHEALTH STARTUP HEALTHYMD LAUNCHES TO TEST, TREAT AND SAVE LIVES

Retrieved on: 
Monday, April 24, 2023
Insurance, Hepatitis, Housing, Centers for Disease Control and Prevention timeline, U.S. Department of Defense Strategy for Operating in Cyberspace, HIV, Infection, Fear, Health equity, Gonorrhea, Pre-exposure prophylaxis, Pharmacy, STD, Black, Hepatitis C, Risk, Genital herpes, Vertically transmitted infection, Office of Inspector General, U.S. Department of Health and Human Services, Transport, Virus, Syphilis, Vaccine

TAMARAC, Fla., April 24, 2023 /PRNewswire/ -- Today HealthyMD announces the launch of its new online sexual health testing and treatment services. The company's mission is to improve and save lives by reducing the stigma and fear around testing for sexually-transmitted diseases (STDs), the viruses hepatitis C and HIV, as well as providing the most advanced pre-exposure prophylaxis (PrEP) treatment available to prevent HIV.

Key Points: 
  • New cases of the hepatitis C virus — which can be, but is not exclusively transmitted via sexual contact — are also increasing, particularly among people ages 18 to 29.
  • If the test results are positive, additional telehealth appointments will be scheduled and if needed, HealthyMD will provide preventive or therapeutic medication(s), including PrEP for HIV.
  • As with HealthyMD, all of their ventures have addressed health inequities often faced by Black, Hispanic, LGBTQIA+, and other communities that have been marginalized.
  • The company is poised to quickly expand, launch an app to extend ease-of-use in addition to its mobile-optimized website, and unveil new strategic partnerships and public health awareness efforts to improve and save lives.

Global Propolis Market Size, Share & Trends Analysis Report 2022: A $746.4 Million Market by 2028 - Increasing Rate of Herpes Simplex Virus Type 1 and Type 2 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022
Alternative Medicine, Health, Natural Resources, Other Natural Resources, Online, Genital herpes, CDC, Pachydactylus labialis, Growth, Population, Tablet, Dermatology, Lichen, Infection, Distribution, Mycosis, CAGR, CSA, Burns, MEA, Propolis, HIV, WHO, Center, Immune system, Industry, Blister, Joint Medical Service (Germany), Capsule, Korea Disease Control and Prevention Agency, Acne, USD, Vaccine

The global propolis market size is expected to reach USD 746.4 million by 2028, registering a CAGR of 2.3%

Key Points: 
  • The global propolis market size is expected to reach USD 746.4 million by 2028, registering a CAGR of 2.3%
    The increasing rate of herpes simplex virus type 1 and type 2 is a major factor propelling the market growth.
  • These infections lead to cold sores and blisters, and are often painful, which, in turn, will drive the market.
  • As per the WHO report 2020, genital herpes infection plays important role in spreading HIV infection.
  • The increasing demand for propolis in the pharmaceutical and healthcare industry is a major factor driving market growth.

Victory Square’s Subsidiary, Draft Label Technologies, Enters Into Definitive Agreement to Complete Business Combination Transaction

Retrieved on: 
Thursday, September 29, 2022
Diamond, Canadian Securities Exchange, Privacy, Compliance, OTC, Physician, Science and technology in Asia, Prospectus, App, Urinary incontinence, Time, Sale, Organization, Company, Acquisition, Testosterone, Treatment, Sensitive, Insurance, Skin, First Nations, ESG, FDA, News, OTCQX, Mental health, Regulation, Genital herpes, GLOBE, SEDAR, STD, VST, Health, Engineering, Letter, Erectile dysfunction, CSE, Solution, Victory Square, Premature ejaculation, AI, Acne, Education, Security (finance), Cryptocurrency, Online shopping, Renewable energy, Online gambling, Risk management, Transaction, Exchange, Fertility

VANCOUVER, British Columbia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Victory Square Technologies Inc. (CSE:VST) (OTC:VSQTF) (“VST” or the “Company”) is pleased to announce that further to the letter of intent entered into on June 23, 2022 (the “LOI”) with 1288273 B.C. Ltd. ("AcquisitionCo") and Draft Label Technologies Inc. (“Draft Label”), a wholly-owned subsidiary of the Company, the Company has entered into a share exchange agreement effective on September 28, 2022, with AcquisitionCo and Draft Label (the “Share Exchange Agreement”), in respect of a business combination pursuant to which AcquisitionCo will acquire all of the equity interests of Draft Label and the shareholders of Draft Label will receive shares of AcquisitionCo in exchange for their holdings in Draft Label (the “Proposed Transaction”).

Key Points: 
  • Ltd. ("AcquisitionCo") and Draft Label Technologies Inc. (Draft Label), a wholly-owned subsidiary of the Company, the Company has entered into a share exchange agreement effective on September 28, 2022, with AcquisitionCo and Draft Label (the Share Exchange Agreement), in respect of a business combination pursuant to which AcquisitionCo will acquire all of the equity interests of Draft Label and the shareholders of Draft Label will receive shares of AcquisitionCo in exchange for their holdings in Draft Label (the Proposed Transaction).
  • In connection with the Proposed Transaction, AcquisitionCo has agreed to provide Draft Label with a bridge loan of $125,000 within five (5) days of the signing of the Share Exchange Agreement, which Draft Label intends to use for working capital purposes.
  • Concurrently to or as soon as possible after the completion of the Proposed Transaction, AcquisitionCo and Draft Label will cause the Resulting Issuer to obtain a final receipt for the Prospectus.
  • This forward-looking information may be affected by risks and uncertainties in the business of the Company, Draft Label and AcquisitionCo and market conditions.

Now More Than Ever Americans Are Open To Exploring Their Sexuality, Hims & Hers’ Nationwide Survey Uncovers The Realities Of Sex In America Today

Retrieved on: 
Tuesday, September 27, 2022
Women, Millennials, Men, Generation Z, Baby Boomers, Health, Generation X, Consumer, General Health, Hims & Hers Health, Pachydactylus labialis, Republican, Patient, United Kingdom, Human sexuality, Perception, Sex, Research, New, Human, OMG, Premature ejaculation, Roe v. Wade, Reproductive rights, Behavior, Man, SVP, Innovation, Gen, Woman, NYSE, Erectile dysfunction, Generation X, Population, Supreme, Pharmacy, Queer, Mental health, Thought, Female, Sexual dysfunction, Report, Homs, Urinary tract infection, Health minister, Candidiasis, Health, Orgasm, Prescription, Hers, Shame, Role-playing, White, Dermatology, Genital herpes, Millennials, Quality of life, Male, Penis, Embarrassment, Multimedia, Education, Generation Z, Hair loss, Sex industry, Birth control, Health insurance, Toy, Medical device, Boomer

The 2022 Report serves as a new educational resource, designed to uncover behaviors, trends, fears, fantasies and realities about sex in America.

Key Points: 
  • The 2022 Report serves as a new educational resource, designed to uncover behaviors, trends, fears, fantasies and realities about sex in America.
  • 75% of America assumes other people have sex once a week or more; whereas only about half of Americans actually do.
  • 42% of America worries that if they dont have frequent sex with their partner, their partner will cheat on them.
  • 63% of America agrees with the statement, My overall quality of life would improve if my sex life improved.

Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases

Retrieved on: 
Wednesday, August 24, 2022
University, COVID-19, Medicine, HBV, Safety, Securities Exchange Act of 1934, Program, Securities Act of 1933, Research, Hepatitis B virus, SAN, Doctor of Philosophy, Genital herpes, Nobel Prize in Physiology or Medicine, Hepatitis, Sumathi Best Television Current Reporting Award, Department of Medical Microbiology (Schering AG), Department, Medical microbiology, SEC, U.S. Securities and Exchange Commission, Degenerative disease, Immunology, Assembly, Nobel Prize, GLOBE, Leadership, Therapy, Investor, Annual report, Q&A, Event, Patient, Vaccine, Pharmaceutical industry, Virology, Physiology, Nobel

SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, plans to host a research webcast on Wednesday, August 31, 2022, from 1:30-2:30 pm PT/4:30-5:30 pm ET. The event will highlight two new small molecule research programs that expand the company’s portfolio beyond core inhibitors and hepatitis B/delta viruses. The first program targets a differentiated antiviral approach against herpes simplex virus type 2 (HSV-2) for patients with recurrent genital herpes. The second is advancing a pan-herpes antiviral for serious transplant-associated viral infections.

Key Points: 
  • The event will highlight two new small molecule research programs that expand the companys portfolio beyond core inhibitors and hepatitis B/delta viruses.
  • The first program targets a differentiated antiviral approach against herpes simplex virus type 2 (HSV-2) for patients with recurrent genital herpes.
  • Assembly Bio is a clinical-stage biotechnology company pioneering the development of novel therapeutics for serious viral diseases.
  • Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Global Genital Herpes Treatment Market Outlook Report 2022-2027 Featuring Key Vendors - GlaxoSmithKline, Glenmark Pharmaceuticals, Viatris, Novartis, Teva Pharmaceuticals, & Bausch Health Companies - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Infectious Diseases, Pharmaceutical, Health, People, FDA, LGBT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Woman, Ageing, Valaciclovir, Pharmacy, Retail, Risk, MSM, Famciclovir, Recurrence, Sex organ, Food, Simplex, Population, NE, Geography, GSK, Incidence, IND, Man, HSV, Patient, HSV-2, Company, Genital herpes, Vaccine, STD, OTC, Infection, Awareness, Immunodeficiency, Sanofi, Herpes labialis, WHO, Technology, Herpes simplex virus, HIV, Factor X, Sex, STI, Vertically transmitted infection, Investigational New Drug, Pharmaceutical industry, Birth control, Aciclovir, Aciclovir, Pritelivir, Moderna

The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography.
  • HSV-2 is the leading virus type segment as HSV-2 is the leading cause of genital herpes.
  • North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%.

Information Update - Apotex recalls additional Apo-Acyclovir tablets due to a nitrosamine impurity

Retrieved on: 
Thursday, July 28, 2022
NDMA, Tablet, Cancer, Shingles, Vegetable, Genital herpes, Recurrence, Patient, Nitrosamine, Dairy, Communication, Risk, Air pollution, Aciclovir, Drinking water, Dietary supplement

This means that long-term exposure to a level above what is considered acceptable may increase the risk of cancer.

Key Points: 
  • This means that long-term exposure to a level above what is considered acceptable may increase the risk of cancer.
  • There is no immediate risk in continuing to take the recalled medication, since the increased risk of cancer typically involves long-term exposure to the nitrosamine impurity above the acceptable level.
  • This is an update to a communication on a previous recall.
  • Please see the full advisory for more information, including more on the risk and what patients should do.

Rational Vaccines Herpes Simplex Type 2 (HSV-2) Therapeutic Vaccine Candidate Demonstrates Efficacy in a Therapeutic Animal Study

Retrieved on: 
Friday, July 8, 2022
Diagnosis, Mouse, Fever, Blister, Patient, School, Biotechnology, Nerve agent, Fissure, Severe cognitive impairment, UC Davis School of Veterinary Medicine, Disease, Louisiana State University, Chills, Erythema, Infection, Company, National, LSU, Simplex, Ulcer, Veterinary medicine, Virology, Guinea, NIH, World, WHO, Western world, Genital herpes, World Health Organization, Myalgia, Virus, Human, Animal, Neonatal infection, Vaccine, Foundation for the National Institutes of Health, HSV-2, HSV, Pharmaceutical industry

WOBURN, Mass. and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2). Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo. In addition, RVX201 appears to generate a robust cellular immune response equivalent to that elicited by wild-type HSV-2 on Day 7 post-infection. Results showed that in comparison to no vaccine, animals that received RVX201 had the number of symptomatic days reduced by 45 percent while those that received gD2-alum/MPL vaccine only had a 24 percent reduction in symptomatic days.

Key Points: 
  • and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced findings from an National Institutes of Health (NIH)-funded pilot study of RVX201, the Company's lead therapeutic vaccine candidate for herpes simplex virus type 2 (HSV-2).
  • Results showed that treatment with RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine or placebo in vivo.
  • The herpes simplex virus (HSV), commonly referred to as herpes, is categorized into two types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).
  • Rational Vaccines is revolutionizing the treatment, prevention, and diagnosis of herpes and herpes-related diseases with its rationally engineered, live-attenuated viral immunotherapeutic and prophylactic vaccine candidates.